Client Resource, Training
After 35 you are losing muscle. After 60 the rate accelerates. Most people have no idea this is happening until functional capacity is already significantly impaired.
Sarcopenia is the progressive loss of skeletal muscle mass, strength, and function that occurs with age. It was formally recognised as a distinct muscle disease by the International Classification of Diseases in 2016 (ICD-10: M62.84). The European Working Group on Sarcopenia in Older People (EWGSOP2, 2019) defines it as the combination of low muscle strength and low muscle mass, with low physical performance indicating severe sarcopenia. This formal classification matters because it shifts sarcopenia from vague “getting weaker with age” to a diagnosable condition with measurable criteria, specific consequences, and evidence-based interventions.
Sarcopenia is not simply about aesthetics or athletic performance. It is the primary mechanism through which ageing adults lose functional independence, the ability to stand from a chair, climb stairs, carry groceries, catch a trip, and live without assistance. Its consequences include increased fall risk, fracture risk, metabolic dysfunction, hospitalisation, and all-cause mortality. And unlike many age-related conditions, it responds substantially to appropriate intervention.
Skeletal muscle mass declines at approximately 3–8% per decade after age 30, accelerating after 60. Muscle strength declines faster than mass (approximately 1.5–5% per year after 50. In adults over 80, sarcopenia prevalence exceeds 50% using current diagnostic criteria. (Baumgartner et al.; Cruz-Jentoft et al. EWGSOP2 2019)
The EWGSOP2 (2019) updated consensus defines probable sarcopenia as low muscle strength alone, grip strength below 27 kg for men or 16 kg for women, or chair stand time above 15 seconds for five stands. Confirmed sarcopenia requires low strength plus low muscle mass. Severe sarcopenia additionally requires low physical performance (gait speed below 0.8 m/s). The shift from the original 2010 definition, which prioritised low muscle mass as the primary criterion, to the updated one, which prioritises low strength, was driven by evidence showing strength is a better predictor of clinical outcomes than mass alone. You can have preserved muscle mass but impaired contractile quality and neural drive, and the functional consequences are the same.
Practical implication: Grip strength and five-times sit-to-stand testing are the primary screening tools for probable sarcopenia. Both are included in The Benchmark assessment.
Longitudinal studies tracking the same individuals over time show that skeletal muscle mass declines at approximately 3–8% per decade from the mid-30s under typical conditions. After 60, the rate of both mass and strength loss accelerates significantly, driven by declining hormones (testosterone, oestrogen, IGF-1, growth hormone), reduced anabolic sensitivity to protein and exercise, increased inflammatory load, and declining neural efficiency. A 70-year-old who has not trained throughout their life may have 30–40% less functional muscle than they had at 30, and may already be below the functional thresholds required for independent living.
The critical window: The third and fourth decades are the most important for establishing the muscle mass baseline that will buffer against later decline. Entering your 50s and 60s with a higher baseline provides significantly more margin before clinical thresholds are crossed.
Sarcopenia results from multiple converging processes. Preferential loss of type II (fast-twitch) muscle fibres begins in the fourth decade, these are the fibres responsible for power, speed, and rapid stabilisation. Motor unit remodelling reduces the number and firing efficiency of neural signals driving muscle contraction. Anabolic resistance, reduced sensitivity of muscle protein synthesis to both dietary protein and exercise stimuli, means older muscle requires larger doses of both training and protein to achieve the same adaptations as younger muscle. Chronic low-grade inflammation (inflammaging) further suppresses muscle protein synthesis and accelerates breakdown. These processes compound each other.
The anabolic resistance implication: An older adult eating 0.8g protein per kg bodyweight and doing moderate exercise may be doing everything by general health guidance standards and still progressing through sarcopenia. Higher protein targets and progressive resistance training are required to overcome anabolic resistance.
The clinical consequences extend well beyond reduced physical capacity. Skeletal muscle is the primary site of insulin-stimulated glucose disposal, so its loss directly worsens metabolic health and increases type 2 diabetes risk. Sarcopenic individuals have longer hospital stays, higher rates of post-surgical complications, slower recovery from illness, and higher all-cause mortality. Falls, driven by reduced strength, power, and proprioception, are a leading cause of injury-related death in adults over 65. Sarcopenia is not a quality-of-life issue; it is a survival issue.
Muscle as an endocrine organ: Skeletal muscle secretes myokines (including IL-6, irisin, and BDNF) that regulate inflammation, insulin sensitivity, fat metabolism, and brain health. Loss of muscle mass is loss of a major endocrine organ, not just a structural problem.
Progressive resistance training is the most consistently supported intervention for preventing, arresting, and partially reversing sarcopenia across all age groups studied. Meta-analyses of resistance training interventions in older adults consistently show significant improvements in muscle mass, strength, power, and functional capacity, even in adults in their 70s and 80s. Adaptations are primarily neural in the first 8–12 weeks and increasingly hypertrophic thereafter. Resistance training directly counters type II fibre atrophy, maintains motor unit density, and reduces inflammatory markers associated with sarcopenic progression.
Dose: Two to three resistance training sessions per week targeting major muscle groups with progressive overload is the minimum effective dose, the same dose identified as optimal for mortality risk reduction in the broader resistance training and longevity literature.
Muscle protein synthesis requires adequate dietary protein. Anabolic resistance in older adults means the required dose is higher than for younger adults. The PROT-AGE study group and ESPEN recommend 1.2–2.0g of protein per kg of bodyweight per day for adults over 65, compared to the standard RDA of 0.8g/kg. For adults actively training against sarcopenia, targets of 1.6–2.2g/kg are supported by the evidence. Distribution matters: 30–40g of protein per meal is needed to maximally stimulate muscle protein synthesis in older adults (approximately double the amount needed in younger adults.
Leucine threshold: Older muscle requires approximately 2.5–3g of leucine per meal to trigger the mTORC1 pathway for muscle protein synthesis. This is found in approximately 25–30g of high-quality protein (meat, fish, eggs, dairy).
Sarcopenia progresses silently. Body weight does not capture it, simultaneous fat gain and muscle loss can leave weight constant while composition deteriorates significantly, a pattern known as sarcopenic obesity that carries particularly high health risk. Appropriate measurement requires body composition assessment (BIA, DXA, or ultrasound) combined with functional testing (grip strength, sit-to-stand speed, balance). Tracking both over time shows whether training and nutrition are maintaining or building muscle mass, whether strength is being preserved relative to age-related norms, and whether functional capacity is improving or declining.
NTCZ relevance: The Benchmark assesses grip strength (VALD DynaMo), leg extension and hip abduction strength, movement quality, and body composition (Omron Karada BIA). This combination maps directly onto the EWGSOP2 diagnostic framework, providing objective data on both muscle strength and mass that can be tracked over successive assessments.
Sarcopenia begins in the mid-30s, accelerates through the 40s and 50s, and becomes clinically significant by the time most people notice it. The window to do something meaningful about it is open now, not in twenty years. By the time functional capacity is visibly impaired, a large portion of the physiological reserve that would have buffered against it has already been lost.
The interventions are not complicated: progressive resistance training at an appropriate dose, adequate protein distributed across meals, and objective measurement to confirm it is working. The Benchmark provides the measurement baseline. The rest is consistent execution.
Book The Benchmark →Cruz-Jentoft AJ et al. (EWGSOP2), Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16–31. The primary clinical diagnostic framework.
Baumgartner RN et al., Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147(8):755–763. Foundational epidemiological data on muscle mass decline rates.
Morley JE et al., Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011;12(6):403–409. Clinical consequences and intervention evidence.
Bauer J et al. (PROT-AGE Study Group), Evidence-based recommendations for optimal dietary protein intake in older people. J Am Med Dir Assoc 2013;14(8):542–559. Protein dosing recommendations for older adults.
Landi F et al., Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 2012;31(5):652–658. Falls risk and sarcopenia evidence.